The Limited Times

Now you can see non-English news...

[New Crown Pneumonia] Long-term medication with low immunity and high risk for patients with lupus erythematosus, government support

2020-03-11T16:11:01.095Z


The outbreak of new coronavirus pneumonia (commonly known as Wuhan pneumonia) continues, and the number of confirmed cases in Hong Kong continues to increase. Patients with lupus erythematosus have a higher risk of contracting new type of coronary pneumonia because they need to take long-term medication to suppress the immune system. Emperor Zhang, an emeritus clinical assistant professor and specialist in rheumatology at the University of Hong Kong, pointed out that the use of biological agents can reduce the risk of severe outbreaks in patients with lupus erythematosus, and there are also studies in the Mainland that refer to lupus erythematosus, a common drug called "hydroxychloroquine", for new coronary pneumonia. It may be effective, or it may help patients with lupus erythematosus fight new coronary pneumonia. Biologics are expensive and patients need insurance to afford them. The patient organization "Joy Club" hopes that the government can provide more funding for medicines to overcome difficulties with patients.


Social News

Written by: Yuan Yan

2020-03-12 00:00

Last updated: 2020-03-12 00:00

The outbreak of new coronavirus pneumonia (commonly known as Wuhan pneumonia) continues, and the number of confirmed cases in Hong Kong continues to increase. Patients with lupus erythematosus have a higher risk of contracting new type of coronary pneumonia because they need to take long-term medication to suppress the immune system. Emperor Zhang, an emeritus clinical assistant professor and specialist in rheumatology at the University of Hong Kong, pointed out that the use of biological agents can reduce the risk of severe outbreaks in patients with lupus erythematosus, and there are also studies in the Mainland that refer to lupus erythematosus, a common drug called "hydroxychloroquine", for new coronary pneumonia. It may be effective, or it may help patients with lupus erythematosus fight new coronary pneumonia.

Biologics are expensive and patients need insurance to afford them. The patient organization "Joy Club" hopes that the government can provide more funding for medicines to overcome difficulties with patients.

Zhang Ye, an emeritus clinical assistant professor and specialist in rheumatology at the University of Hong Kong, pointed out that patients with lupus erythematosus who have a weak immune system are at higher risk of infection than ordinary people. If they are unfortunately infected, they are more likely to have complications. (Provided by respondents)

Lupus erythematosus is a disorder of the autoimmune system. Most of the patients are women. At present, about 12,000 people are diagnosed in Hong Kong. When the disease occurs, the patient's body will produce abnormal antibodies that attack the tissues and organs in the body. The patient needs long-term medication to suppress the immune system. Zhang Ye, an emeritus clinical assistant professor of rheumatology at the University of Hong Kong, points out that the immune system is weak. People with lupus have a higher risk of infection than ordinary people. If they are unfortunately infected, they are more likely to have complications.

Doctor: Biologics may be effective for new coronary pneumonia

Zhang continued that biologics are an adjuvant treatment that can help patients maintain a low level of activity, reduce the risk of severe attacks, and help reduce the cumulative dose of steroids used by patients, ultimately reducing the occurrence of organ damage. He added that mainland experts found that the commonly used drug for the treatment of lupus erythematosus, "Hydroxychloroquine," may be effective for new coronary pneumonia, and may have the opportunity to help patients with lupus erythematosus to fight against new coronary pneumonia. The patient bears the burden.

Patients are prone to complications when multiple illnesses occur repeatedly

Li Yanxian was diagnosed with lupus erythematosus in 2006. She has experienced repeated illnesses over the years. She has experienced hair loss and rotten face. In severe cases, her lungs were attacked by the immune system, and she was difficult to breathe, which caused pleural inflammation and hepatitis. She needed to stay in bed for months. In the course of treatment, she had used biologics to assist the treatment, but she needed to be supported by insurance before she could afford 8,000 yuan per month. Now she has no choice but to stop using biologics and must take steroids for a long time to control her condition.

The "Le Club", which provides support for patients with lupus erythematosus, said that new self-injection pens for biological agents have been released. Patients can inject themselves at home, instead of spending hours or half a day in the hospital, and reducing the need for patients to enter and leave the hospital. The number of times I hope the government can provide more funding for the drug and pay attention to patients with lupus erythematosus.

▼ Hong Kong masks, panic buying, conflict, winter under the epidemic ▼

+10

+9

+8

[New Coronary Pneumonia] 13 clinics in the Department of Health provide collection boxes for patients to take saliva samples by themselves

[New Crown Pneumonia] HA: If N95 surface is not contaminated, extended use will not increase the risk of infection

[New crown pneumonia] Cathay flight attendant confirmed to return to Hong Kong from Madrid

[Support field] Lupus patients preach happy philosophy, don't treat patients as monsters

Du Xiaoqiao is optimistic in the face of lupus erythematosus and suffering from nephritis: a high dose of steroids

Wuhan pneumonia lupus erythematosus

Source: hk1

All news articles on 2020-03-11

You may like

Life/Entertain 2024-02-01T15:10:04.617Z
Life/Entertain 2024-02-05T14:30:54.106Z
Life/Entertain 2024-02-02T06:59:25.078Z

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z
News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.